Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Immutep ADS Representing 10 Ord Shs IMMP

Healthcare Biotechnology
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:IMMP)

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

GlobeNewswire 2 days ago

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

GlobeNewswire 8 days ago

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire 9 days ago

Immutep Announces First Clinical Data from 90mg Dosing of Efti

GlobeNewswire March 5, 2024

Immutep Quarterly Activities Report Q2 FY24

GlobeNewswire January 30, 2024

First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer

GlobeNewswire January 4, 2024

Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire December 21, 2023

Immutep Receives A$2.6 million R&D Tax Incentive from French Government

GlobeNewswire December 7, 2023

Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial

GlobeNewswire November 22, 2023
View More News ››

Opinion & Analysis (NDAQ:IMMP)

Immuno-oncology Pure Play 'Ideally Positioned to Capture Value'

Streetwise Reports February 7, 2018
View More Opinion ››

Bullboard Posts (NDAQ:IMMP)

Why Australian Cancer Biotech Firm Immutep Stock Is Soaring

Just In: $IMMP Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday? | BenzingaWednesday,@Immutep Limited@(NASDAQ...
whytestocks - 2 days ago

it's a buy today for me

at this low price,taking a chance,so glta.
coolfooldumbguy - March 22, 2019
View more Bullboard ››

Calima Energy Ord Shs

Calima Energy Ord Shs

Calima Energy Limited is an Australia-based production-focused energy company. The Company is engaged in the exploration and ...
View More »